Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The user has been using dutasteride for 8 months, oral minoxidil for 3 years, and topical minoxidil on temples, with recent microneedling. They experienced thinning after switching from finasteride to dutasteride and are hoping for improvement by the 12-month mark.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

A user experienced significant hair regrowth after 3 months of using 2.5mg oral minoxidil but also noticed unwanted body hair growth. Suggestions included switching to dutasteride or adding finasteride to address hair loss more effectively.

The user has been taking finasteride for nearly two months and has noticed an increased urge to urinate with slight discomfort. They are questioning if this side effect is temporary.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

The conversation discusses various factors affecting hair loss, not just DHT, and mentions treatments like Minoxidil, finasteride, and melatonin. Some users report personal experiences with these treatments and hormone tests, while others speculate on the role of hormones like prolactin and cortisol in hair loss.

OP reported significant hair regrowth using oral minoxidil 5mg, dutasteride 0.5mg, and dermastamping. Users discussed side effects, effectiveness of treatments, and debated dermastamp needle sizes.

A 21 year old's progress journey with hair loss, using finasteride, dutasteride, and oral minoxidil to successfully regrow hair. The user also suggests abstaining from masturbation and porn for the first 30 days in order to manage potential side effects of these treatments.

The user experienced significant hair thickening and temple hair growth after one year of using finasteride, minoxidil, and weekly dermarolling. They are considering asking their dermatologist about dutasteride.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

The conversation is about seeking recommendations for clinics in Los Angeles that offer dutasteride mesotherapy for hair loss treatment. The user is asking for experiences and suggestions from the community.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

Dutasteride users have mixed results in hair loss treatment, with some experiencing improvements and others worsening. Some report metabolic changes like weight gain or diabetes, while others have no significant side effects.

The user has been using a regimen of dutasteride (DUT) and topical minoxidil (1ml once a day) for six months, resulting in hair regrowth and increased thickness. The user reports no side effects and mentions that the shedding phase lasted about a month.

The user is experiencing increased hair miniaturization despite using oral minoxidil, dutasteride, and microneedling. They are considering reintroducing finasteride and adjusting dutasteride dosage.

Hair loss discussion involves pyrilutamide treatment. Slow regrowth observed, expecting 10 baby hairs on temple regions after 1 year.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

Hair loss treatments, specifically 5AR inhibitors, can impact neurosteroids and sexual health. The effects of topical fin/dut on tissue-specific DHT levels are unclear.

A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.

A 24-year-old male with diffuse thinning has been using finasteride for two years, dutasteride for 6-7 months, and oral minoxidil for 5 months, along with topical treatments. He plans to continue this regimen and reassess in August 2026, hoping to stabilize hair loss without surgery.